What happened
Poongjeon Pharmacy reported consolidated results for FY2025: revenue of US$16.5M (+2795.6% year on year), an operating loss of US$3.11M and a net loss of US$315K.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$16.5M |
|---|---|
| Revenue vs a year earlier | +2795.6% |
| Operating profit | −US$3.11M |
| Net income | −US$315K |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-23, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260223900656 → open original filing |
Source: DART. Information only, not investment advice.